[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100420005":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":43,"centralContacts":48,"locations":53,"responsibleParty":415,"collaborators":28,"id":417,"slug":418,"hasResults":419,"nctId":420,"briefTitle":421,"officialTitle":422,"acronym":423,"eligibilityCriteria":424,"healthyVolunteers":419,"sex":425,"minAge":426,"maxAge":28,"enrollmentInfo":427,"targetDuration":28,"studyType":430,"phases":431,"briefSummary":434,"conditions":435,"keywords":28,"overallStatus":56,"whyStopped":28,"lastUpdateSubmitDate":438,"lastUpdatePostDateStruct":439,"startDateStruct":442,"completionDateStruct":444,"leadSponsor":446,"locationsCount":447},{"fullName":5,"class":6},"Institut du Cancer de Montpellier - Val d'Aurelle","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental: Arm A: immediate rectal surgery","EXPERIMENTAL","\"Very good\" responder patients will be randomly assigned to proctectomy performed within 4 to 6 weeks from randomization.",[13,14,15],"Drug: Induction chemotherapy - modified FOLFIRINOX regimen","Other: Early tumor response evaluation by MRI volumetry","Procedure: Radical proctectomy with total mesorectal excision",{"label":17,"type":18,"description":19,"interventionNames":20},"RCT Cap 50 and then rectal surgery","ACTIVE_COMPARATOR","Very good\" responder patients will be randomly assigned to receive chemoradiotherapy combining the administration of oral capecitabine (1600 mg\u002Fm2\u002Fday, BID) and radiotherapy at a total dose of 50 grays (2Gy\u002Fday, 5 days a week, 5 weeks, boost 6 Gy) followed after 7 weeks by a proctectomy.",[13,14,21,15],"Radiation: Radiochemotherapy Cap 50",[23,29,33,38],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Induction chemotherapy - modified FOLFIRINOX regimen","An induction chemotherapy (6 cycles) combining irinotecan 180 mg\u002Fm2, oxaliplatin 85 mg\u002Fm2, elvorin 200 mg\u002Fm2 followed by a 46-hour continuous infusion 2,400 mg\u002Fm2) will be delivered every 15 days (D1=D15).",[9,17],null,{"type":6,"name":30,"description":31,"armGroupLabels":32,"otherNames":28},"Early tumor response evaluation by MRI volumetry","Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.",[9,17],{"type":34,"name":35,"description":36,"armGroupLabels":37,"otherNames":28},"RADIATION","Radiochemotherapy Cap 50","RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or Intensity-Modulated RadioTherapy (IMRT) (2 Gy per fraction, 5 fractions per week during 5 weeks \u002F 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg\u002Fm2 per day delivered the days of radiotherapy treatment (2 daily intake).",[17],{"type":39,"name":40,"description":41,"armGroupLabels":42,"otherNames":28},"PROCEDURE","Radical proctectomy with total mesorectal excision","The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.",[9,17],[44],{"name":45,"affiliation":46,"role":47},"Philippe Rouanet, MD","Philippe.Rouanet@icm.unicancer.fr","STUDY_CHAIR",[49],{"name":45,"role":50,"phone":51,"phoneExt":52,"email":46},"CONTACT","4 67 61 30 71","+33",[54,75,85,97,110,123,137,150,163,176,189,202,218,231,244,257,270,279,291,302,311,320,329,340,352,364,373,382,391,403],{"facility":55,"status":56,"city":57,"state":58,"zip":59,"country":60,"countryCode":61,"cosmosGeoPoint":62,"geoPoint":67,"contacts":68},"Institut Paoli Calmettes","RECRUITING","Marseille","Bouches Du Rhône","13009","France","FR",{"type":63,"coordinates":64},"Point",[65,66],5.38107,43.29695,{"lat":66,"lon":65},[69,73],{"name":70,"role":50,"phone":71,"phoneExt":52,"email":72},"Bernard Lelong, MD","4-91-22-36-60","lelongb@ipc.unicancer.fr",{"name":70,"role":74,"phone":28,"phoneExt":28,"email":28},"PRINCIPAL_INVESTIGATOR",{"facility":76,"status":77,"city":57,"state":58,"zip":78,"country":60,"countryCode":61,"cosmosGeoPoint":79,"geoPoint":81,"contacts":82},"Hôpital Nord de Marseille","NOT_YET_RECRUITING","13015",{"type":63,"coordinates":80},[65,66],{"lat":66,"lon":65},[83],{"name":84,"role":74,"phone":28,"phoneExt":28,"email":28},"Laura Beyer-Berjot, MD",{"facility":86,"status":56,"city":57,"state":87,"zip":88,"country":60,"countryCode":61,"cosmosGeoPoint":89,"geoPoint":91,"contacts":92},"Hôpital Européen de MARSEILLE","Bouches-du-rhône","13003",{"type":63,"coordinates":90},[65,66],{"lat":66,"lon":65},[93,96],{"name":94,"role":50,"phone":28,"phoneExt":28,"email":95},"Charles VANBRUGGHE, MD","c.vanbrugghe@hopital-europeen.fr",{"name":94,"role":74,"phone":28,"phoneExt":28,"email":28},{"facility":98,"status":56,"city":99,"state":100,"zip":101,"country":60,"countryCode":61,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"CHU Besançon","Besançon","Doubs","25030",{"type":63,"coordinates":103},[104,105],6.01815,47.24878,{"lat":105,"lon":104},[108],{"name":109,"role":74,"phone":28,"phoneExt":28,"email":28},"Zaher Lakkis, MD",{"facility":111,"status":56,"city":112,"state":113,"zip":114,"country":60,"countryCode":61,"cosmosGeoPoint":115,"geoPoint":119,"contacts":120},"CHU de Bordeaux","Bordeaux","Gironde","33600",{"type":63,"coordinates":116},[117,118],-0.58046,44.84124,{"lat":118,"lon":117},[121],{"name":122,"role":74,"phone":28,"phoneExt":28,"email":28},"Bernard Celerier, MS",{"facility":124,"status":56,"city":125,"state":126,"zip":127,"country":60,"countryCode":61,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Insitut Régional du Cancer de Montpellier","Montpellier","Hérault","34298",{"type":63,"coordinates":129},[130,131],3.87635,43.61093,{"lat":131,"lon":130},[134,136],{"name":45,"role":50,"phone":135,"phoneExt":52,"email":46},"04-67-61-31-50",{"name":45,"role":74,"phone":28,"phoneExt":28,"email":28},{"facility":138,"status":56,"city":139,"state":140,"zip":141,"country":60,"countryCode":61,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"CHU de Nancy","Vandœuvre-lès-Nancy","Lorraine","54511",{"type":63,"coordinates":143},[144,145],6.17114,48.66115,{"lat":145,"lon":144},[148],{"name":149,"role":74,"phone":28,"phoneExt":28,"email":28},"Adeline Germain, MD",{"facility":151,"status":56,"city":152,"state":153,"zip":154,"country":60,"countryCode":61,"cosmosGeoPoint":155,"geoPoint":159,"contacts":160},"Centre Alexis Vautrin","Nancy","Meurthe Et Moselle","54519",{"type":63,"coordinates":156},[157,158],6.18496,48.68439,{"lat":158,"lon":157},[161],{"name":162,"role":74,"phone":28,"phoneExt":28,"email":28},"Frédéric Marchal, MD",{"facility":164,"status":56,"city":165,"state":166,"zip":167,"country":60,"countryCode":61,"cosmosGeoPoint":168,"geoPoint":172,"contacts":173},"Centre Oscart Lambret","Lille","Nord","59000",{"type":63,"coordinates":169},[170,171],3.05512,50.63391,{"lat":171,"lon":170},[174],{"name":175,"role":74,"phone":28,"phoneExt":28,"email":28},"Mehrdad Jafari, MD",{"facility":177,"status":56,"city":178,"state":179,"zip":180,"country":60,"countryCode":61,"cosmosGeoPoint":181,"geoPoint":185,"contacts":186},"CHU Amiens","Amiens","Picardie","80054",{"type":63,"coordinates":182},[183,184],2.3,49.9,{"lat":184,"lon":183},[187],{"name":188,"role":74,"phone":28,"phoneExt":28,"email":28},"Jean-Marc Regimbeau, MD",{"facility":190,"status":56,"city":191,"state":192,"zip":193,"country":60,"countryCode":61,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"CHU Clermont-Ferrand","Clermont-Ferrand","Puy De Dôme","63000",{"type":63,"coordinates":195},[196,197],3.08682,45.77969,{"lat":197,"lon":196},[200],{"name":201,"role":74,"phone":28,"phoneExt":28,"email":28},"Anne Dubois, MD",{"facility":203,"status":56,"city":204,"state":205,"zip":206,"country":60,"countryCode":61,"cosmosGeoPoint":207,"geoPoint":211,"contacts":212},"CH PAU","Pau","Pyrénées-atlantiques","64000",{"type":63,"coordinates":208},[209,210],-0.35583,43.31117,{"lat":210,"lon":209},[213,217],{"name":214,"role":50,"phone":215,"phoneExt":52,"email":216},"Juliette THAURY, MD","559724983","juliette.thaury@ch-pau.fr",{"name":214,"role":74,"phone":28,"phoneExt":28,"email":28},{"facility":219,"status":56,"city":220,"state":221,"zip":222,"country":60,"countryCode":61,"cosmosGeoPoint":223,"geoPoint":227,"contacts":228},"CHU de Lyon","Lyon","Rhône","69310",{"type":63,"coordinates":224},[225,226],4.84789,45.74906,{"lat":226,"lon":225},[229],{"name":230,"role":74,"phone":28,"phoneExt":28,"email":28},"Eddy Cotte, MD",{"facility":232,"status":77,"city":233,"state":234,"zip":235,"country":60,"countryCode":61,"cosmosGeoPoint":236,"geoPoint":240,"contacts":241},"CH Annecy","Annecy","Savoie","74330",{"type":63,"coordinates":237},[238,239],6.12565,45.90878,{"lat":239,"lon":238},[242],{"name":243,"role":74,"phone":28,"phoneExt":28,"email":28},"Mathieu Baconnier, MD",{"facility":245,"status":56,"city":246,"state":247,"zip":248,"country":60,"countryCode":61,"cosmosGeoPoint":249,"geoPoint":253,"contacts":254},"CHU Rouen","Rouen","Seine-Maritime","76031",{"type":63,"coordinates":250},[251,252],1.09932,49.44313,{"lat":252,"lon":251},[255],{"name":256,"role":74,"phone":28,"phoneExt":28,"email":28},"Jean-Jacques Tuech, MD",{"facility":258,"status":56,"city":259,"state":260,"zip":261,"country":60,"countryCode":61,"cosmosGeoPoint":262,"geoPoint":266,"contacts":267},"Hôpital Bicêtre","Le Kremlin-Bicêtre","Val De Marne","94270",{"type":63,"coordinates":263},[264,265],2.36073,48.81471,{"lat":265,"lon":264},[268],{"name":269,"role":74,"phone":28,"phoneExt":28,"email":28},"Antoine Brouquet, MD",{"facility":271,"status":56,"city":112,"state":28,"zip":272,"country":60,"countryCode":61,"cosmosGeoPoint":273,"geoPoint":275,"contacts":276},"Bordeaux Colorectal Institute","33300",{"type":63,"coordinates":274},[117,118],{"lat":118,"lon":117},[277],{"name":278,"role":74,"phone":28,"phoneExt":28,"email":28},"Quentin Denost, MD",{"facility":280,"status":77,"city":281,"state":28,"zip":282,"country":60,"countryCode":61,"cosmosGeoPoint":283,"geoPoint":287,"contacts":288},"Centre Georges-François Leclerc","Dijon","21079",{"type":63,"coordinates":284},[285,286],5.01391,47.31344,{"lat":286,"lon":285},[289],{"name":290,"role":74,"phone":28,"phoneExt":28,"email":28},"Cédric Chevalier, MD",{"facility":292,"status":56,"city":293,"state":28,"zip":28,"country":60,"countryCode":61,"cosmosGeoPoint":294,"geoPoint":298,"contacts":299},"Chu Grenoble","Grenoble",{"type":63,"coordinates":295},[296,297],5.71479,45.17869,{"lat":297,"lon":296},[300],{"name":301,"role":74,"phone":28,"phoneExt":28,"email":28},"Bertrand Trilling, MD",{"facility":303,"status":56,"city":165,"state":28,"zip":304,"country":60,"countryCode":61,"cosmosGeoPoint":305,"geoPoint":307,"contacts":308},"Chu Lille","59037",{"type":63,"coordinates":306},[170,171],{"lat":171,"lon":170},[309],{"name":310,"role":74,"phone":28,"phoneExt":28,"email":28},"Guillaume Piessen, MD",{"facility":312,"status":56,"city":220,"state":28,"zip":28,"country":60,"countryCode":61,"cosmosGeoPoint":313,"geoPoint":315,"contacts":316},"CAC Léon Bérard",{"type":63,"coordinates":314},[225,226],{"lat":226,"lon":225},[317,319],{"name":318,"role":50,"phone":28,"phoneExt":28,"email":28},"Michel Rivoire, MD",{"name":318,"role":74,"phone":28,"phoneExt":28,"email":28},{"facility":321,"status":56,"city":57,"state":28,"zip":322,"country":60,"countryCode":61,"cosmosGeoPoint":323,"geoPoint":325,"contacts":326},"Hôpital La Timone","13005",{"type":63,"coordinates":324},[65,66],{"lat":66,"lon":65},[327],{"name":328,"role":74,"phone":28,"phoneExt":28,"email":28},"Laetitia Dahan, MD",{"facility":330,"status":56,"city":331,"state":28,"zip":28,"country":60,"countryCode":61,"cosmosGeoPoint":332,"geoPoint":336,"contacts":337},"Centre Antoine Lacassagne","Nice",{"type":63,"coordinates":333},[334,335],7.26608,43.70313,{"lat":335,"lon":334},[338],{"name":339,"role":74,"phone":28,"phoneExt":28,"email":28},"Ludovic Evesque, MD",{"facility":341,"status":56,"city":342,"state":28,"zip":343,"country":60,"countryCode":61,"cosmosGeoPoint":344,"geoPoint":348,"contacts":349},"CHU de Nîmes","Nîmes","30029",{"type":63,"coordinates":345},[346,347],4.35788,43.83665,{"lat":347,"lon":346},[350],{"name":351,"role":74,"phone":28,"phoneExt":28,"email":28},"Martin Bertrand, MD",{"facility":353,"status":56,"city":354,"state":28,"zip":355,"country":60,"countryCode":61,"cosmosGeoPoint":356,"geoPoint":360,"contacts":361},"Hôpital Saint-Louis","Paris","75010",{"type":63,"coordinates":357},[358,359],2.3488,48.85341,{"lat":359,"lon":358},[362],{"name":363,"role":74,"phone":28,"phoneExt":28,"email":28},"Léon Maggiori, MD",{"facility":365,"status":56,"city":354,"state":28,"zip":366,"country":60,"countryCode":61,"cosmosGeoPoint":367,"geoPoint":369,"contacts":370},"Hôpital Saint-Antoine","75012",{"type":63,"coordinates":368},[358,359],{"lat":359,"lon":358},[371],{"name":372,"role":74,"phone":28,"phoneExt":28,"email":28},"Jérémie Lefèvre, MD",{"facility":374,"status":56,"city":354,"state":28,"zip":375,"country":60,"countryCode":61,"cosmosGeoPoint":376,"geoPoint":378,"contacts":379},"Hôpital Européen Georges-Pompidou","75015",{"type":63,"coordinates":377},[358,359],{"lat":359,"lon":358},[380],{"name":381,"role":74,"phone":28,"phoneExt":28,"email":28},"Mehdi Karoui, MD",{"facility":383,"status":56,"city":354,"state":28,"zip":384,"country":60,"countryCode":61,"cosmosGeoPoint":385,"geoPoint":387,"contacts":388},"Hôpital Diaconesses","75020",{"type":63,"coordinates":386},[358,359],{"lat":359,"lon":358},[389],{"name":390,"role":74,"phone":28,"phoneExt":28,"email":28},"Alain Valverde, MD",{"facility":392,"status":56,"city":393,"state":28,"zip":394,"country":60,"countryCode":61,"cosmosGeoPoint":395,"geoPoint":399,"contacts":400},"Institut de Cancérologie de l'Ouest","Saint-Herblain","44800",{"type":63,"coordinates":396},[397,398],-1.651,47.21154,{"lat":398,"lon":397},[401],{"name":402,"role":74,"phone":28,"phoneExt":28,"email":28},"Frédéric Dumont, MD",{"facility":404,"status":56,"city":405,"state":28,"zip":406,"country":60,"countryCode":61,"cosmosGeoPoint":407,"geoPoint":411,"contacts":412},"CHU de Toulouse","Toulouse","31059",{"type":63,"coordinates":408},[409,410],1.44367,43.60426,{"lat":410,"lon":409},[413],{"name":414,"role":74,"phone":28,"phoneExt":28,"email":28},"Laurent Ghouti, MD",{"type":416,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100420005","phase-2-study-evaluating-the-tailored-management-of-locally-advanced-rectal-carcinoma-100420005",false,"NCT04749108","Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma","Multicentric Phase II-III Study Evaluating the Tailored Management of Locally-advanced Rectal Carcinoma After a Favorable Response to Induction Chemotherapy","GRECCAR14","INCLUSION CRITERIA FOR SCREENING\n\n1. Written consent,\n2. Patient who receive Folfirinox,\n3. Patient aged over 18 years old,\n4. World Health Organization (WHO) performance status ≥ 1,\n5. Histologically confirmed diagnosis of adenocarcinoma of the rectum,\n6. Distal part of the tumor from 1 to 12 cm from the upper part of the levator ani (dynamic rectal examination),\n7. No unequivocal evidence on CT-Scan of established metastatic disease,\n8. MRI evaluation of the locally advanced tumor before neoadjuvant chemotherapy:\n\n   1. Predictive CRM \\\u003C 2 mm\n   2. Or T3c-d (extending ≥ 5 mm beyond the muscularis propria) with extra mural venous invasion (EMVI)\n   3. Or T4a-b (except bone and sphincteric invasion).\n\nNON INCLUSION CRITERIA FOR SCREENING\n\n1. Non measurable rectal tumor or not assessed by MRI before inclusion,\n2. Ultra-low rectal tumor at diagnosis which imposes radiotherapy administration (inferior tumor pole less than 1 cm from the upper part of the levator ani).\n3. Active cardiac disease including any of the following: a. Congestive heart failure ≥ New York Heart Association (NYHA) class 2 (appendix 4), b. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months), c. Myocardial infarction less than 6 months before first dose of treatment, d. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta blockers or digoxin are permitted),\n4. Previous or concurrent cancer that is distinct in primary site or histology from colorectal cancer within 5 years prior to study inclusion, except for curatively treated cervical cancer in situ, non-melanoma skin cancer and superficial bladder tumors \\[Ta (non invasive tumor), Tis (carcinoma in situ) and T1 (lamina propria invasion)\\],\n5. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), deep vein thrombosis or pulmonary embolism within 6 months before start of treatment.\n\nINCLUSION CRITERIA FOR EXPERIMENTAL TREATMENT\n\n1. WHO performance status 0-1,\n2. Patient with tumoral regression ≥ 60% and CRM ≥ 1mm,\n3. No unequivocal evidence on CT-Scan of established metastatic disease,\n4. General condition considered suitable for radical pelvic surgery and a systemic therapy with Capecitabine\n5. Adequate hematologic, hepatic, renal and ionogram function assessed within 7 days prior to study treatment a. Platelet count ≥ 100,000\u002Fmm3; Hemoglobin (Hb) ≥ 9 g\u002FdL; Absolute neutrophil count (ANC) ≥ 1,500\u002F mm3 b. Total bilirubin ≤ 1.5 x Upper Limit Normal (ULN), Alkaline phosphatases ≤ 3 x ULN and ASpartate aminoTransferase (AST) and ALanine aminoTransferase (ALT) ≤ 3 x ULN, c. Serum creatinine ≤ 1.5 x ULN or calculated creatinine clearance ≥ 50 ml\u002Fmin according to Modification of Diet in Renal Disease (MDRD),\n6. For women of reproductive potential, negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test obtained within 7 days before the start of study treatment. Women not of reproductive potential are female patients who are postmenopausal or permanently sterilized (e.g., tubal occlusion, hysterectomy, bilateral salpingectomy),\n7. For women of childbearing potential and men, agreement to use an adequate contraception for the duration of study participation and up to 6 months following completion of therapy. Females of childbearing potential who are sexually active with a non-sterilized male partner must use 2 methods, of effective contraception. The investigator or a designated associate is requested to advise the patient on how to achieve an adequate birth control. Adequate contraception is defined in the study as any medically recommended method (or combination of methods) as per standard of care,\n8. No evidence of chronic or acute ischemic heart disease,\n9. Willing to participate to the study, and able to give informed consent and to comply with the treatment and follow-up schedules,\n10. Affiliation to the French Social Security System.\n\nNON-INCLUSION CRITERIA FOR EXPERIMENTAL TREATMENT\n\n1. Patient with a history of pelvic radiotherapy,\n2. Contraindication to chemotherapy and\u002For radiotherapy,\n3. Complete or partial Dihydropyrimidine deshydrogenase (DPD) deficiency (uracilemia ≥ 16 ng\u002FmL),\n4. Any infection that could jeopardize treatment administration,\n5. Any other serious concomitant disease or disorder that may interfere with the patient's participation in the study and safety during the study (e.g., severe liver, heart, kidney, lung, metabolic, or psychiatric disorders),\n6. History of inflammatory bowel disease,\n7. Patients with a history of pulmonary fibrosis or interstitial pneumonia,\n8. Patients using antivitamin K (Coumadin etc…) but it's possible to substitute the antivitamin K treatment with low molecular weight heparins (LMWHs) before starting chemotherapy,\n9. Known hypersensitivity to Capecitabine drug, study drug classes, or any constituent of the products,\n10. Patient who received live attenuated vaccine within 10 days of inclusion,\n11. Pregnant or breastfeeding woman. If a patient is of childbearing age, she must have a negative pregnancy test (serum β-hCG) documented 72 hours prior to inclusion,\n12. Patient treated with an investigational drug within the last 30 days,\n13. Patient under curatorship or guardianship or safeguard justice,\n14. Inability to submit to medical monitoring of the trial for geographical, social or psychological reasons.","ALL","18 Years",{"count":428,"type":429},1075,"ESTIMATED","INTERVENTIONAL",[432,433],"PHASE2","PHASE3","Locally advanced rectal carcinoma raise the issue of both the oncological control, local and general, and the therapeutic morbidity. Surgery alone can cure only one out of two patients, radiochemotherapy improves the local control but the metastatic risk remains about 30% with enhanced postoperative morbidity and poor functional results. The tumor response to preoperative treatment is the major prognostic factor which revealed the aggressiveness of the tumor. To this day, there are no biologic predictive markers for tumor response.\n\nThe purpose of this trial is to tailor the management according to the early tumoral response after short and intensive induction chemotherapy. MRI volumetric tumor response will be used to distinguish between good responders and bad responders.\n\n\"Very good\" responders will be randomized to either immediate surgery or radiochemotherapy followed by surgery (Standard arm: Cap 50).",[436,437],"Locally Advanced Malignant Neoplasm","Rectal Carcinoma","2026-02-03",{"date":440,"type":441},"2026-02-05","ACTUAL",{"date":443,"type":441},"2021-11-26",{"date":445,"type":429},"2026-08",{"name":5,"class":6},30]